Civic AI
Procurement intelligence
Federal contract award
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
THE JOHNS HOPKINS UNIVERSITY · Department of Health and Human Services
- Value
- $4,617,504
- Start
- Aug 23, 2023
- End
- Jul 22, 2026
- Action date
- May 10, 2026
- PIID
- 75N93023F00004
- Status
- active
- NAICS
- 541714 · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- Place of performance
- BALTIMORE, MD
- Award type
- DELIVERY ORDER
Description
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
Need modifications, related awards, and vendor peers? Open the full award workspace.